September 2017

New Product - Ocrevus

Ocrevus (ocrelizumab) is a recombinant humanised anti-CD20 monoclonal antibody that selectively targets CD20-expressing B-cells. The precise mechanisms through which ocrelizumab exerts its therapeutic clinical effects in multiple sclerosis (MS) are not fully elucidated but is presumed to involve immunomodulation through the reduction in the number and function of CD20-expressing B-cells. Ocrevus is indicated for the treatment of relapsing forms of multiple sclerosis (RMS) to delay the progression of physical disability and to reduce the frequency of relapse; treatment of primary progressive multiple sclerosis (PPMS) to delay the progression of physical disability. Ocrevus concentrate for solution for infusion 300 mg in 10 mL is supplied in a 15 mL vial, pack of 1.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au